Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
AVENUE THERAPEUTICS, INC. entered into License Agreement with AnnJi Pharmaceutical Co. Ltd. valued at Initial cash license fee of $3.0 million ($2.0 million within 60 days, $1.0 million within 180 days) (effective 2023-02-28).
- Action
- entry
- Agreement
- license
- Counterparty
- AnnJi Pharmaceutical Co. Ltd.
- Value
- Initial cash license fee of $3.0 million ($2.0 million within 60 days, $1.0 million within 180 days)
- Effective
- 2023-02-28
Exact text from the filing
On February 28, 2023, Avenue Therapeutics, Inc. (the “ Company ”) entered into a license agreement with AnnJi Pharmaceutical Co. Ltd., a Taiwanese company (“ AnnJi ”), whereby the Company obtained an exclusive license (the “ License Agreement ”) from AnnJi to intellectual property rights pertaining to the molecule known as JM17, which activates Nrf1 and Nrf2, enhances androgen receptor degradation and underlies AJ201, a clinical product candidate currently in a Phase 1b/2a clinical trial in the U.S. for the treatment of spinal and bulbar muscular atrophy (“ SBMA ”), also known as Kennedy’s Disease. Under the License Agreement, in exchange for exclusive (as described below) rights to the intellectual property underlying the AJ201 product candidate, the Company will pay an initial cash license fee of $3.0 million, of which $2.0 million is payable within 60 days and $1 million payable within 180 days after the effective date of the License Agreement. The Company is also obligated to issue
View on SEC.gov